Lariciresinol

Research use only, not for human use.

Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.

Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.(In Vitro):In this study, the antifungal properties and mode of action of Lariciresinol were investigated. Lariciresinol displays potent antifungal properties against several human pathogenic fungal strains without hemolytic effects on human erythrocytes. To understand the antifungal mechanism of action of Lariciresinol, the membrane interactions of Lariciresinol were examined. Fluorescence analysis using the membrane probe 3,3'-diethylthio-dicarbocyanine iodide (DiSC(3)-5) and 1,6-diphenyl-1,3,5-hexatriene (DPH), as well as a flow cytometric analysis with propidium iodide (PI), a membrane-impermeable dye, indicated that Lariciresinol was associated with lipid bilayers and induced membrane permeabilization.

——

——

——

Angiogenesis

VEGFR

VEGFR

——

——

27003-73-2

360.406

C20H24O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (277.47 mM)

COc1cc(C[C@H]2CO[C@@H]([C@H]2CO)c2ccc(O)c(OC)c2)ccc1O

——

(-20℃)

With Ice Pack

≥ 2 years